Lea Strohm, Andreas Daiber, Henning Ubbens, Roopesh Krishnankutty, Matthias Oelze, Marin Kuntic, Omar Hahad, Veronique Klein, Imo E Hoefer, Alex von Kriegsheim, Hartmut Kleinert, Dorothee Atzler, Philipp Lurz, Christian Weber, Philipp S Wild, Thomas Münzel, Christoph Knosalla, Esther Lutgens, Steffen Daub
CD40L-CD40-TRAF signaling plays a role in atherosclerosis progression and affects the pathogenesis of coronary heart disease (CHD). We tested the hypothesis that CD40L-CD40-TRAF signaling is a potential therapeutic target in hyperlipidemia, diabetes, and hypertension. In mouse models of hyperlipidemia plus diabetes (db/db mice) or hypertension (1 mg/kg/d angiotensin-II for 7 days), TRAF6 inhibitor treatment (2.5 mg/kg/d for 7 or 14 days) normalized markers of oxidative stress and inflammation...
March 30, 2024: Basic Research in Cardiology